Vitamin D Treatment in Primary Hyperparathyroidism: A Randomized Placebo Controlled Trial

Lars Rolighed, Lars Rejnmark, Tanja Sikjaer, Lene Heickendorff, Peter Vestergaard, Leif Mosekilde, Peer Christiansen

Research output: Contribution to journalJournal articleResearchpeer-review

128 Citations (Scopus)

Abstract

Context: Low 25-hydroxy vitamin D (25OHD) levels are common in patients with primary hyperparathyroidism (PHPT) and associated with higher PTH levels and hungry bone syndrome following parathyroidectomy (PTX). However, concerns have been raised on safety of vitamin D supplementation in PHPT. Objective: We aimed to assess safety and effects on calcium homeostasis and bone metabolism of supplementation with high doses of vitamin D in PHPT patients. Design, Setting: This was an investigator-initiated double-blind, randomized, placebo-controlled, parallel-group trial from a single center. Patients: Forty-six PHPT patients were recruited, mean age of 58 (range 29-77) years and 35 (76%) were women. Interventions: Daily supplementation with 70 microgram (2800 IU) cholecalciferol or identical placebo for 52 weeks. Treatment was administered 26 weeks prior to PTX and continued for 26 weeks after PTX. Main Outcome Measures: PTH, calcium homeostasis, and bone metabolism. Results: Preoperatively, 25OHD increased from 50 to 94 nmol/L in the treatment group and decreased from 57 to 52 nmol/L in the placebo group (p
Original languageEnglish
Article numberjc20133978
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number3
Pages (from-to)1072-1080
Number of pages9
ISSN0021-972X
DOIs
Publication statusPublished - 13 Jan 2014

Fingerprint

Dive into the research topics of 'Vitamin D Treatment in Primary Hyperparathyroidism: A Randomized Placebo Controlled Trial'. Together they form a unique fingerprint.

Cite this